Technical Analysis for KMDA - Kamada Ltd.

Grade Last Price % Change Price Change
grade C 5.73 0.00% 0.00
KMDA closed unchanged on Friday, May 17, 2019, on 42 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Flat
See historical KMDA trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Pocket Pivot Bullish Swing Setup -1.72%
Earnings Movers Other -1.72%
Inside Day Range Contraction -1.72%
20 DMA Resistance Bearish -0.35%
50 DMA Resistance Bearish -0.35%
200 DMA Support Bullish -0.35%
Pocket Pivot Bullish Swing Setup -0.35%
Wide Range Bar Range Expansion -0.35%
Earnings Movers Other -0.35%

Older signals for KMDA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Kamada Ltd., a biopharmaceutical company, develops, produces, and markets therapeutics based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases; Heparin Lock Flush to maintain potency of intravenous injection device; Kamacaine 0.5%, a spinal and epidural anesthesia; and Albumin for therapeutic plasma exchange and hypovolemic shock. In addition, the company offers Factor IX for treatment of bleeding episodes and to maintain plasma factor IX levels; Factor VIII, VWF for the treatment of bleeding episodes to maintain plasma factor VIII level, vonwillebrand disease; and Human Transferrin for in vitro and diagnostic use. Its development stage products include Aerosolized AAT, which is in Phases II-III clinical trials for alpha-1 antitrypsin deficiency, and under Phase II clinical trial for bronchiectasis, as well as completed Phase II clinical trial for cystic fibrosis; Human Transferrin for pharmaceutical use; and snake antiserum for snake bites. The company has a collaboration partnership with PARI for the development of an aerosolized AAT treatment. Kamada Ltd. sells its products through distributors worldwide, as well as is involved in marketing of imported complementing products in Israel. The company was founded in 1990 and is headquartered in Ness Ziona, Israel.
Medicine Biopharmaceutical Cystic Fibrosis Anatomy Blood Cardiac Surgery Antitrypsin Deficiency Blood Products Coagulation System Coagulation Alpha 1 Antitrypsin Bronchiectasis Heparins Immune Thrombocytopenic Purpura
Is KMDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.7
52 Week Low 4.63
Average Volume 100,915
200-Day Moving Average 5.6298
50-Day Moving Average 5.8748
20-Day Moving Average 5.8373
10-Day Moving Average 5.725
Average True Range 0.1832
ADX 13.59
+DI 19.2654
-DI 19.1796
Chandelier Exit (Long, 3 ATRs ) 5.7904
Chandelier Exit (Short, 3 ATRs ) 6.0896
Upper Bollinger Band 6.1961
Lower Bollinger Band 5.4785
Percent B (%b) 0.35
BandWidth 12.293355
MACD Line -0.0538
MACD Signal Line -0.0476
MACD Histogram -0.0062
Fundamentals Value
Market Cap 214.3 Million
Num Shares 37.4 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -114.60
Price-to-Sales 2.15
Price-to-Book 2.76
PEG Ratio 9.35
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.88
Resistance 3 (R3) 5.89 5.84 5.86
Resistance 2 (R2) 5.84 5.81 5.84 5.85
Resistance 1 (R1) 5.79 5.78 5.82 5.78 5.84
Pivot Point 5.74 5.74 5.76 5.74 5.74
Support 1 (S1) 5.69 5.71 5.72 5.68 5.62
Support 2 (S2) 5.64 5.68 5.64 5.61
Support 3 (S3) 5.59 5.64 5.61
Support 4 (S4) 5.58